Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Stoke Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Stoke Therapeutics's regulatory disclosures and financial reporting.
Stoke Therapeutics Chief Patient Officer Jason Hoitt reported mandated share sales to cover taxes on vested stock units. On March 17–18, 2026, he sold a total of 3,712 shares of common stock in open-market transactions required to satisfy tax withholding obligations. Sale prices were based on weighted averages, with individual trades occurring in ranges between $30.59 and $33.855 per share. After these transactions, he directly holds 10,276 shares, and no remaining stock options or other derivatives are reported.
Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported open‑market sales of 8,895 shares of common stock in multiple transactions on March 17–18. A footnote states these sales were issuer‑mandated to satisfy tax withholding liabilities from vesting restricted stock units. After the transactions, he holds 28,836 shares of common stock directly.
Morgan Stanley Smith Barney LLC lists proposed sales of Common shares in a Form 144 notice. The filing shows a proposed sale tied to an exercise of stock options dated 03/19/2026 for 1,365 shares and restricted stock units dated 12/01/2025 for 96 shares.
Stoke Therapeutics, Inc. filed a shelf registration and prospectus to offer $150,000,000 of common stock for sale from time to time under an at-the-market Controlled Equity Sales Agreement. The Sales Agreement with Cantor Fitzgerald & Co. permits offers from time to time after effectiveness.
The prospectus discloses that approximately 3.2 million shares have previously been sold for aggregate net proceeds of $87.8 million under an earlier prospectus supplement. The company states proceeds usage is general corporate purposes, including clinical development and manufacturing.
Stoke Therapeutics Chief Patient Officer Jason Hoitt exercised 10,000 restricted stock units into 10,000 shares of common stock. This was a derivative exercise (code M), not an open-market purchase or sale. Following the transaction, he directly owned 13,988 shares of common stock and 30,000 RSUs.
Each RSU converts into one share of common stock upon settlement. The RSU award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service. The reported ownership total also reflects 2,186 shares previously acquired through the company’s employee stock purchase plan.
Stoke Therapeutics Chief Financial Officer Thomas Leggett exercised restricted stock units into common shares in a routine compensation-related transaction. On March 15, 2026, he exercised 14,750 restricted stock units, receiving 14,750 shares of common stock at an exercise price of $0.00 per share.
After the transaction, Leggett directly holds 14,750 shares of common stock and 44,250 restricted stock units. Each RSU represents the right to receive one share of common stock upon settlement, and the award vests in four equal annual installments beginning on March 15, 2026, subject to his continued service with the company.
Stoke Therapeutics, Inc. chief medical officer Barry Ticho reported the vesting and exercise of restricted stock units into common shares. On March 15, 2026, RSU awards covering 33,850 shares of common stock were settled at a price of $0.00 per share.
These RSU awards each represent the right to receive one share of common stock upon settlement and vest in annual 25% installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, subject to continued service. Following these transactions, Ticho directly holds 53,648 shares of Stoke Therapeutics common stock.
Stoke Therapeutics director Edward M. Kaye, MD, increased his direct equity stake through RSU settlements. On March 15, 2026, he exercised or settled restricted stock units covering 61,750 shares of Common Stock at a stated price of $0.00 per share, reflecting equity compensation rather than open‑market purchases.
The RSU awards vest in annual installments of one quarter of the total shares beginning on March 15, 2024 and March 15, 2025, contingent on continued service. Following these transactions, Kaye directly holds 110,874 shares of Stoke Therapeutics Common Stock.
Stoke Therapeutics, Inc. reported that its General Counsel and Corporate Secretary, Jonathan Allan, exercised restricted stock units and acquired common shares. On March 15, 2026, he exercised derivative awards covering 25,475 restricted stock units, each representing one share of common stock, at an exercise price of $0.00 per unit.
These exercises resulted in the acquisition of 25,475 shares of common stock, bringing his directly held common stock position to 37,731 shares following the transactions. Footnotes explain that each RSU converts into one share and that the RSU awards vest in annual installments beginning on March 15, 2024, March 15, 2025, and March 15, 2026, contingent on continued service.
Stoke Therapeutics director Arthur A. Levin reported an open-market sale of 605 shares of Common Stock at $36.80 per share on March 13, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 12, 2025.
After this sale, Levin directly holds 4,237 shares of Stoke Therapeutics common stock and indirectly holds 17,979 shares through the Butler-Levin Revocable Trust, where he serves as trustee.